In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways' synthetic psilocybin COMP360 clears Phase 3 trials, showing 39% depression reduction in 24 hours for treatment-resistant patients.

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

F OR FIVE years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot. On February 17th Compass ...

Danaher Corp. has agreed to acquire Masimo Corp. for $9.9 billion in a move to strengthen its diagnostics business. Under the terms of the agreement, Danaher will acquire all the outstanding shares of ...

Compass Pathways has announced the successful achievement of the primary endpoint in the ongoing Phase III COMP006 trial, the ...

Some places are less a stop and more a story, and Casa Bonita at 6715 W Colfax Ave, Lakewood, Colorado, turns a simple meal ...

The voice comes to Nicole in the silent moments between passing storms. Under barn rafters of roughhewn hemlock from long ...

His range was like a swinging pendulum of human temperament, allowing him to be bellowing and destructive or discreet and vulnerable - sometimes within a single film or even a single scene.

1. “Upside-Down Magic (Volume 1),” Sarah Mlynowski. Middle grade, ages 8-12. A group of students must learn how to navigate ...

Midweek needs a breather spot, someplace that lets you pause without making a production of it. At 825 Walnut St in Boulder, ...